N Eng J Med 2008, 358:36–46.CrossRef 10. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk selleck screening library C, Atmaca A, Bokemeyer C, Knuth A, Jäger E: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitgemeinschaft internistische onkologie. J Clin Oncol 2008, 26:1435–1442.PubMedCrossRef 11. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P,
Bedenne L, Milan C: Randomized multicenter phase II trial of a biweekly regimen of fluouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously GW-572016 manufacturer untreated metastatic gastric cancer: a Fédération Francophone de Cáncerologie Digestive Group Study – FFCD 9803. J Clin Oncol 2004, 22:4319–4328.PubMedCrossRef 12. Thuss-Patience P, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P: Survival advantage
for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitgemeinschaft Internische Onkologie (AIO ) . Eur J Cancer 2011, 15:2306–2314.CrossRef 13. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012, 30:1513–1518.PubMedCrossRef Buspirone HCl 14. Kim R, Tan A, Choi M, El-Rayes BF: Geographic differences in approach to advanced gastric cancer: Is there a standard approach? Crit Rev Oncol Hematol 2013. doi: 10.1016/j.critrevonc.2013.05.007. [Epub ahead of print] 15. Di Lauro L, Sergi D, Belli F, Fattoruso SI, Arena MG, Pizzuti L, Vici P: Docetaxel,
oxaliplatin, and capecitabine (DOX) combination chemotherapy for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma [abstract ]. J Clin Oncol 2013,31(Suppl):e15065. 16. Di Lauro L, Belli F, Arena MG, Carpano S, Paoletti G, Giannarelli D, Lopez M: Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann Oncol 2005, 16:1498–1502.PubMedCrossRef 17. Di Lauro L, Giacinti L, Arena MG, Sergi D, Fattoruso SI, Giannarelli D, Lopez M: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res 2009, 28:34.PubMedCrossRef 18. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma.